Amundi’s Inhibrx, Inc. Common Stock INBX Stock Holding History

Amundi’s Portfolio INBX Stock Details INBX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-465	Closed	-$11K	–	2152
2022 Q4	$11K	Buy	+465	New	+$13.7K	﹤0.01%	1838

Other funds holding INBX

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

Amundi's INBX Position: Q1 2023 in Review

Amundi sold out of Inhibrx, Inc. Common Stock (INBX) in Q1 2023, closing a stake of 465 shares — an estimated $11K sold.

Amundi first reported a position in INBX in Q4 2022 and held it in 1 quarter. The position peaked at $11K in Q4 2022. 108 funds tracked by Wall St. Rank hold INBX as of Q1 2023.

Amundi reported no remaining Inhibrx, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
Amundi sold 465 Inhibrx, Inc. Common Stock shares in Q1 2023, an estimated $11K.
Amundi first reported a position in Inhibrx, Inc. Common Stock in Q4 2022 and held it in 1 quarter.
Amundi's Inhibrx, Inc. Common Stock position peaked at $11K in Q4 2022.
108 funds tracked by Wall St. Rank held Inhibrx, Inc. Common Stock as of Q1 2023.

Based on Amundi's 13F filing for Q1 2023, filed 15 May 2023.